Vistagen Therapeutics (VTGN) Research & Development (2016 - 2025)
Vistagen Therapeutics (VTGN) has disclosed Research & Development for 14 consecutive years, with $14.2 million as the latest value for Q4 2025.
- Quarterly Research & Development rose 25.81% to $14.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $52.0 million through Dec 2025, up 42.12% year-over-year, with the annual reading at $39.4 million for FY2025, 96.66% up from the prior year.
- Research & Development hit $14.2 million in Q4 2025 for Vistagen Therapeutics, down from $15.9 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $15.9 million in Q3 2025 to a low of $3.9 million in Q3 2023.
- Historically, Research & Development has averaged $9.3 million across 5 years, with a median of $9.6 million in 2021.
- Biggest five-year swings in Research & Development: soared 321.38% in 2021 and later crashed 72.55% in 2023.
- Year by year, Research & Development stood at $7.8 million in 2021, then decreased by 11.89% to $6.9 million in 2022, then tumbled by 33.81% to $4.5 million in 2023, then skyrocketed by 149.17% to $11.3 million in 2024, then rose by 25.81% to $14.2 million in 2025.
- Business Quant data shows Research & Development for VTGN at $14.2 million in Q4 2025, $15.9 million in Q3 2025, and $11.7 million in Q2 2025.